TapImmune to Present at the 3rd Annual Growth Capital Expo in Las Vegas on May 4, 2016

JACKSONVILLE, FL, April 28, 2016 / TapImmune,Inc. (TPIV), a clinical-stage immune-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced it will be presenting at the 3rd Annual Growth Capital Expo to be held on May 3rd – 5th, 2016 at Caesars Palace in Las Vegas, Nevada.

The Company presentation will be given at 8.00 am on Wednesday, May 4th by Dr. John N. Bonfiglio a TapImmune Board member and Strategic Advisor. Entry into Phase II clinical programs in breast and ovarian cancer will be discussed.

TapImmune management will be available for one-on-one investor meetings. The company’s presentation will be webcast through the following link: http://wsw.com/webcast/gce3/.

About Growth Capital Expo

The Growth Capital Expo is the premier conference for emerging growth company finance featuring:

Presentations by selected MicroCap and pre-IPO growth company management teams showcasing the best opportunities of the year for emerging growth investment
Two full days of educational panels and presentations by the leading practitioners of investment in public and late-stage private emerging growth companies as well as a half-day educational pre-conference for executive managers of pre-IPO and recently public companies

Click here to signup and listen to the Webinar online.

About TapImmune Inc.

TapImmune Inc. is an immuno-oncology company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The Company’s peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients’ killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company’s technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company’s website at markertherapeutics.com for details.

Forward-Looking Statement Disclaimer

This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements”. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.


TapImmune Inc.,

Glynn Wilson, Ph.D.

Chairman & CEO